Jazz Pharmaceuticals plc Cash Flow-to-Debt Ratio
Jazz Pharmaceuticals plc cash flow-to-debt ratio. Jazz Pharmaceuticals plc (J7Z) has a Cash Flow-to-Debt Ratio of 0.06x as of March 2026, meaning its operating cash flow of €408.20 Million could theoretically repay 0% of its total liabilities (€7.33 Billion) in one year. Check J7Z cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Jazz Pharmaceuticals plc (2013–2025)
Cash flow-to-debt ratio of Jazz Pharmaceuticals plc from 2013 to 2025. Historical debt coverage capacity for Jazz Pharmaceuticals plc across 13 annual periods. Check J7Z capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Jazz Pharmaceuticals plc Cash Flow-to-Debt Ratio by Year (2013–2025)
Jazz Pharmaceuticals plc cash flow-to-debt ratio by year from 2013 to 2025. Year-by-year debt coverage analysis for Jazz Pharmaceuticals plc. For the full cash flow conversion analysis, see J7Z cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.18x | €1.36 Billion | €7.34 Billion | ▲ +4.8% |
| 2024 | 0.18x | €1.40 Billion | €7.92 Billion | ▲ +23.6% |
| 2023 | 0.14x | €1.09 Billion | €7.66 Billion | ▼ -13.1% |
| 2022 | 0.16x | €1.27 Billion | €7.75 Billion | ▲ +75.7% |
| 2021 | 0.09x | €778.51 Million | €8.33 Billion | ▼ -70.1% |
| 2020 | 0.31x | €899.65 Million | €2.88 Billion | ▼ -2.2% |
| 2019 | 0.32x | €776.40 Million | €2.43 Billion | ▼ -2.1% |
| 2018 | 0.33x | €798.90 Million | €2.45 Billion | ▲ +13.6% |
| 2017 | 0.29x | €693.09 Million | €2.41 Billion | ▲ +41.9% |
| 2016 | 0.20x | €592.39 Million | €2.92 Billion | ▼ -33.9% |
| 2015 | 0.31x | €531.94 Million | €1.73 Billion | ▲ +48.1% |
| 2014 | 0.21x | €407.61 Million | €1.97 Billion | ▼ -32.3% |
| 2013 | 0.31x | €288.43 Million | €942.69 Million | — |